← Back to Search

Financial Incentives for Type 2 Diabetes (LIFT-FINANCE Trial)

N/A
Waitlist Available
Led By Rebekah J Walker, PhD
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical diagnosis of type 2 diabetes
Age 21 years or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6-months post randomization
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if financial incentives can help improve HbA1c, blood pressure, and quality of life in food insecure adults with type 2 diabetes.

Who is the study for?
This trial is for adults over 21 with type 2 diabetes, an HbA1c of 9 or higher, and who struggle to afford food. They must speak English and not have dementia, drug/alcohol dependency, severe mental disorders, be in another diabetes study, or have less than a six-month life expectancy.
What is being tested?
The study tests if financial rewards can help people with type 2 diabetes eat better and manage their blood sugar levels. Participants will receive one of three types of cash incentives plus monthly educational materials about managing diabetes through diet.
What are the potential side effects?
There are no direct medical side effects from participating in this trial as it involves financial incentives and education rather than medication. However, changes in diet based on the provided information could indirectly affect health.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with type 2 diabetes.
Select...
I am 21 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6-months post randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6-months post randomization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Glycemic control (HbA1c)
Secondary study objectives
Blood pressure (both systolic and diastolic)
Quality of life as measured by the Short Form Health Survey (SF-12)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financial IncentiveExperimental Treatment4 Interventions
Individuals assigned to this group will receive diabetes education, a monthly incentive to supplement income and enhance ability to purchase healthy food options, an additional weekly incentive if receipt for purchase of healthy food items from a grocery store is provided, and an incentive at the end of the study based on absolute drop in HbA1c.
Group II: Monthly Unconditional Plus Healthy Food Purchasing Financial IncentiveExperimental Treatment3 Interventions
Individuals assigned to this group will receive diabetes education, a monthly incentive to supplement income and enhance ability to purchase healthy food options, and an additional weekly incentive if receipt for purchase of healthy food items from a grocery store is provided.
Group III: Monthly Unconditional Financial IncentiveExperimental Treatment2 Interventions
Individuals assigned to this group will receive diabetes education and a monthly incentive to supplement income and enhance ability to purchase healthy food options.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Diabetes Education
2019
Completed Phase 3
~2550

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
631 Previous Clinical Trials
1,181,806 Total Patients Enrolled
State University of New York at BuffaloLead Sponsor
268 Previous Clinical Trials
52,180 Total Patients Enrolled
Rebekah J Walker, PhDPrincipal InvestigatorMedical College of Wisconsin
1 Previous Clinical Trials
300 Total Patients Enrolled

Media Library

Glycemic Control Financial Incentive Clinical Trial Eligibility Overview. Trial Name: NCT05352022 — N/A
Type 2 Diabetes Research Study Groups: Monthly Unconditional Plus Healthy Food Purchasing Plus Glycemic Control Financial Incentive, Monthly Unconditional Plus Healthy Food Purchasing Financial Incentive, Monthly Unconditional Financial Incentive
Type 2 Diabetes Clinical Trial 2023: Glycemic Control Financial Incentive Highlights & Side Effects. Trial Name: NCT05352022 — N/A
Glycemic Control Financial Incentive 2023 Treatment Timeline for Medical Study. Trial Name: NCT05352022 — N/A
~74 spots leftby Apr 2027